Shandong Luoxin Pharmaceutical Group, a well-established pharma company in China, and Yuhan Corporation, one of the largest pharmaceutical companies in South Korea, have entered into a license and co-development agreement under which Luoxin will acquire exclusive rights in China—including Hong Kong and Macau—to develop, manufacture and distribute YH25448, a novel, 3rd -generation EGFR targeted therapy for the treatment of non-small-cell-lung-cancer (NSCLC) patients. A global data report has e...